U
US Pathology Labs
US Pathology Labs provider of anatomic pathology and oncology testing services with a focus on the outpatient market
About US Pathology Labs
US Pathology Labs, Inc. (US LABS), based in Irvine, California, established itself as a national anatomic pathology reference laboratory focused on cancer testing for the outpatient market. The company specialized in providing diagnostic, prognostic, and predictive cancer testing services. Its primary client base included hospitals, physician offices, and surgery centers.
A significant milestone in the company's history was the definitive agreement announced in December 2004 for its acquisition by Laboratory Corporation of America® Holdings (LabCorp). The all-cash transaction was valued at approximately $155 million and was finalized in the first quarter of 2005. This acquisition was a strategic move for LabCorp to enhance its anatomic pathology services and expand its cancer strategy. The deal allowed LabCorp to utilize US LABS' California facility for other esoteric and genomic testing. The management team of US LABS, including CEO Judd Jessup, agreed to continue in their roles as part of LabCorp to ensure a smooth integration of the complementary capabilities of both organizations.
The business model of US LABS centered on offering comprehensive, high-quality, and rapid-response cancer testing. This focus on anatomic pathology and oncology testing services addressed a critical need in the healthcare market for specialized diagnostics outside of the traditional hospital lab setting. The acquisition by LabCorp represented a consolidation trend in the diagnostic laboratory industry, combining US LABS' specialized oncology focus with LabCorp's broader testing capabilities and national reach.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Dec 2004 | $0 | — | LabCorp | — |
| SERIES E✓Equity / VC | Jan 2002 | $13M | $52M | Accel · Highland Capital Partners · Apax Partners · ABS Capital Partners | — |
Growth signals
Latest recorded traffic for US Pathology Labs is 0 monthly website visits. US Pathology Labs's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later5 investors entered at this stage
Accel
Highland Capital Partners
Apax Partners
ABS Capital Partners- SPSage Venture Partners
Other known investors1 additional known investor
LabCorp
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about US Pathology Labs on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See US Pathology Labs’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.